SEARCHCOHORTgastroenterology, endocrinology

cohort·gastroenterology, endocrinology, internal medicine, clinical nutrition, epidemiology·PMC10045849

Polyunsaturated and Saturated Oxylipin Plasma Levels Allow Monitoring the Non-Alcoholic Fatty Liver Disease Progression to Severe Stages

Antioxidants · 13 authors, 7 centres

AI SUMMARY

FIDELITY 100%

This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.

AGENT 01 · STRUCTURED SUMMARY

TRACE TO SOURCE

“

TL;DR

This cross-sectional study of 90 metabolic syndrome patients found that plasma levels of several oxylipins, including arachidonic acid and EPA, were significantly higher in patients with severe hepatic steatosis (NAFLD grade 3) compared to those without or with milder disease.

Full summary

540 CHARS

Hepatic steatosis was graded using MRI-estimated proton density fat fraction (MI-PDFF), classifying patients into four groups (IFC0: without NAFLD; IFC1-3: increasing steatosis severity). Key results showed that plasma levels of arachidonic acid (AA), eicosapentaenoic acid (EPA), and several oxylipin derivatives (e.g., ETA, MaR1, LXB4) were significantly elevated in the most severe NAFLD group (IFC3) compared to other groups. Malondialdehyde (MDA), a marker of lipid peroxidation, was significantly higher in the IFC2 group versus IFC0.

STUDY TYPE

cohort

SPECIALTY

gastroenterology

SUMMARISED BY

AI pipeline

FIDELITY CHECK

100% · A

ORIGINAL PAPER

PMC10045849

Polyunsaturated and Saturated Oxylipin Plasma Levels Allow Monitoring the Non-Alcoholic Fatty Liver Disease Progression to Severe Stages

Antioxidants

READ THE FULL PAPER

ABSTRACT

Abstract Hepatic fat accumulation is the hallmark of non-alcoholic fatty liver disease (NAFLD). Our aim was to determine the plasma levels of oxylipins, free polyunsaturated fatty acids (PUFA) and markers of lipid peroxidation in patients with NAFLD in progressive stages of the pathology. Ninety 40–60-year-old adults diagnosed with metabolic syndrome were distributed in without, mild, moderate or severe NAFLD stages. The free PUFA and oxylipin plasma levels were determined by the UHPLC–MS/MS system. The plasma levels of oxylipins produced by cyclooxygenases, lipoxygenases and cytochrome P450, such as prostaglandin 2α (PGF2α), lipoxinB4 and maresin-1, were higher in severe NAFLD patients, pointing to the coexistence of both inflammation and resolution processes. The plasma levels of the saturated oxylipins 16-hydroxyl-palmitate and 3-hydroxyl-myristate were also higher in the severe NAFLD patients, suggesting a dysregulation of oxidation of fatty acids. The plasma 12-hydroxyl-estearate (12HEST) levels in severe NAFLD were higher than in the other stages, indicating that the hydroxylation of saturated fatty acid produced by reactive oxygen species is more present in this severe stage of NAFLD. The plasma levels of 12HEST and PGF2α are potential candidate biomarkers for diagnosing NAFLD vs. non-NAFLD. In conclusion, the NAFLD progression can be monitored by measuring the plasma levels of free PUFA and oxylipins characterizing the different NAFLD stages or the absence of this disease in metabolic syndrome patients. Keywords: fatty acids, fatty liver, inflammation, metabolic syndrome, oxylipins

CITATION EXPORT

Miguel D Ferrer, Clara Reynés, Margalida Monserrat-Mesquida et al.. Polyunsaturated and Saturated Oxylipin Plasma Levels Allow Monitoring the Non-Alcoholic Fatty Liver Disease Progression to Severe Stages. Antioxidants. (2023). https://doi.org/10.3390/antiox12030711

AUTHORS

13 · 7 CENTRES

Miguel D Ferrer, Clara Reynés, Margalida Monserrat-Mesquida, Magdalena Quetglas-Llabrés, Cristina Bouzas, Silvia García, David Mateos, Miguel Casares, Cristina Gómez, Lucía Ugarriza, Josep A Tur, Antoni Sureda, Antoni Pons

1Research Group in Community Nutrition and Oxidative Stress, University of the Balearic Islands-IUNICS, 07122 Palma de Mallorca, Spain; [email protected] (M.D.F.);
2Research Group in Community Nutrition and Oxidative Stress, Health Research Institute of Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain
3CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain
4Radiodiagnosis Service, Red Asistencial Juaneda, 07011 Palma de Mallorca, Spain
5Clinical Analysis Service, University Hospital Son Espases, 07198 Palma de Mallorca, Spain
6Camp Redó Primary Health Care Center, 07010 Palma de Mallorca, Spain
7Laboratori de Ciències de l’Activitat Física, Universitat de les Illes Balears, 07122 Palma de Mallorca, Spain